Brentuximab vedotin ( DrugBank: Brentuximab vedotin, Brentuximab )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
49全身性エリテマトーデス1
51全身性強皮症3

49. 全身性エリテマトーデス


臨床試験数 : 993 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02533570
(ClinicalTrials.gov)
July 20159/7/2015Dose Ranging Study of Brentuximab Vedotin in Adults With LupusA Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: Brentuximab vedotin;Drug: PlaceboSeagen Inc.NULLTerminated18 YearsN/AAll20Phase 2United States

51. 全身性強皮症


臨床試験数 : 525 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05149768
(ClinicalTrials.gov)
September 1, 202324/11/2021Open Label Extension Study of Brentuximab Vedotin in Early dcSScAn Open Label Extension Study of Brentuximab Vedotin Treatment in Active Diffuse Cutaneous Systemic Sclerosis (Diffuse Scleroderma)Diffuse Cutaneous Systemic SclerosisDrug: Brentuximab vedotinLawson Health Research InstituteSeagen Inc.Not yet recruiting18 YearsN/AAll10Phase 2NULL
2NCT03198689
(ClinicalTrials.gov)
May 7, 201914/6/2017Brentuximab Vedotin in Early Diffuse Cutaneous Systemic SclerosisA Pilot Study of Adcetris Treatment in Active Diffuse Cutaneous Systemic Sclerosis (Diffuse Scleroderma)Diffuse Cutaneous Systemic SclerosisDrug: Brentuximab VedotinLawson Health Research InstituteSeagen Inc.Active, not recruiting18 YearsN/AAll11Phase 2Canada
3NCT03222492
(ClinicalTrials.gov)
September 20, 201717/7/2017Brentuximab Vedotin for Systemic SclerosisEvaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)Diffuse Cutaneous Systemic Sclerosis;Scleroderma;dcSScBiological: Brentuximab Vedotin;Biological: PlaceboNational Institute of Allergy and Infectious Diseases (NIAID)Immune Tolerance Network (ITN);Seagen Inc.;PPD;Rho Federal Systems Division, Inc.Active, not recruiting18 Years70 YearsAll17Phase 1/Phase 2United States;Canada